RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Glenmark is the first company in India to market the innovative FDC of Indacaterol
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
Covaxin was earlier approved for children 12-18 years of age
Subscribe To Our Newsletter & Stay Updated
